TY  - JOUR
AU  - D'Arrigo, Joseph
PY  - 2019
DA  - 2019/06/17
TI  - Treating Dementia Early: Limiting Cellular Damage in Brain Tissue
JO  - OBM Geriatrics
SP  - 057
VL  - 03
IS  - 02
AB  - Much evidence has been published which indicates that microvascular endothelial dysfunction, due to cerebrovascular risk factors (e.g., atherosclerosis, hypertension, obesity, diabetes, smoking, aging), precedes cognitive decline in Alzheimer's disease and contributes to its pathogenesis. By incorporating appropriate drug(s) into biomimetic (lipid cubic phase) nanocarriers, one obtains a multitasking combination therapeutic which targets certain cell-surface scavenger receptors, and crosses the blood-brain barrier (BBB). Such targeting allows for various Alzheimer's-related cell types to be simultaneously searched out, in vivo, for localized drug treatment. This in vivo targeting advantage may be particularly important for repurposing FDA-approved drug(s), especially one which has shown the added ability to restore some cognitive functions in certain animal models of Alzheimer's disease.
SN  - 2638-1311
UR  - https://doi.org/10.21926/obm.geriatr.1902057
DO  - 10.21926/obm.geriatr.1902057
ID  - D'Arrigo2019
ER  -